Browse the corpus

Liddle syndrome, also known as pseudohyperaldosteronism, is a rare hereditary cause of early-onset, resistant hypertension resulting from a gain-of-function mutation in the epithelial sodium channel of the distal nephron. This mutation promotes excessive sodium reabsorption and potassium excretion, leading to hypertension, hypokalemia, and metabolic alkalosis. The syndrome follows an autosomal dominant inheritance pattern characterized by low plasma renin and aldosterone levels, distinguishing it from other mineralocorticoid excess states. Phenotypic variability and incomplete penetrance can obscure recognition, often resulting in delayed diagnosis or misclassification as essential hypertension or primary hyperaldosteronism. Without timely intervention, patients face increased risks of cardiovascular and renal complications, including heart failure, stroke, and chronic kidney disease. Early identification and targeted treatment with epithelial sodium channel inhibitors such as amiloride or triamterene are essential for controlling blood pressure and preventing disease progression. Through participation in this activity, clinicians strengthen their ability to identify, diagnose, and manage Liddle syndrome by integrating clinical findings, biochemical profiles, and genetic testing. Learners gain practical insight into differentiating this condition from other causes of pseudohyperaldosteronism and selecting appropriate pharmacologic therapies. The course emphasizes interprofessional collaboration among primary care clinicians, nephrologists, endocrinologists, genetic counselors, and pharmacists to enhance diagnostic accuracy, optimize therapeutic management, and ensure ongoing monitoring. Coordinated communication within the care team supports timely intervention, patient education, and long-term disease control. Objectives: Determine the appropriate evaluation to establish a diagnosis of Liddle syndrome, including potential differential diagnoses. Implement appropriate treatment strategies, including initiation of epithelial sodium channel blockers and a low-sodium diet, as first-line therapy for managing hypertension and electrolyte abnormalities in patients with Liddle syndrome, while considering individual patient characteristics and comorbidities.

Determine the appropriate evaluation to establish a diagnosis of Liddle syndrome, including potential differential diagnoses. Implement appropriate treatment strategies, including initiation of epithelial sodium channel blockers and a low-sodium diet, as first-line therapy for managing hypertension and electrolyte abnormalities in patients with Liddle syndrome, while considering individual patient characteristics and comorbidities. Assess the effectiveness of treatment interventions and monitor for potential complications of Liddle syndrome, such as electrolyte imbalances and cardiovascular sequelae, through regular clinical evaluations and laboratory monitoring. Collaborate with interprofessional healthcare teams, including primary care clinicians, endocrinologists, nephrologists, and genetic counselors, to facilitate comprehensive evaluation, diagnosis, and management of Liddle syndrome. Access free multiple choice questions on this topic.

Liddle syndrome is one of the rare causes of resistant hypertension that can present in early childhood, although some cases are not detected until adulthood. First described in 1963 by Grant Liddle et al, this syndrome is characterized by a primary increase in sodium reabsorption in the distal nephron leading to subsequent potassium secretion. For this reason, it is also known as pseudohyperaldosteronism. The syndrome is a rare, monogenic, autosomal dominant cause of secondary hypertension resulting from a genetic gain-of-function mutation of the epithelial sodium channel (ENaC).[1] Affected patients typically present with hypertension, hypokalemia, and metabolic alkalosis. Although these findings are similar to those seen in other disorders caused by mineralocorticoid excess, Liddle syndrome does not respond to aldosterone antagonism (eg, spironolactone). The mainstay of treatment is with ENaC blockers, including amiloride.

Liddle syndrome is a congenital disorder typically caused by a single-gene mutation. Patients inherit the disorder in an autosomal dominant pattern with variable penetrance, and diverse populations are affected by the syndrome. Results from genetic studies have determined that this syndrome results from a gain-of-function mutation in the epithelial sodium channel in the distal nephron. In 1995, Hansson et al discovered the germline mutation in the SCNN1G gene as a cause of Liddle syndrome.[2] Later, researchers showed that the ENaC comprises 3 homologous subunits, α-, β-, and γENaC, coded by SCNN1A, SCNN1B, and SCNN1G genes.[3] Mutations in α-, β-, or γENaC subunits lead to amplified activity of this channel, independent of aldosterone activity. While these are the well-described mutations associated with Liddle syndrome, a systematic review by GranhØj et al in 2024 listed 45 unique genetic variants across 86 families (40 of which were diagnostic).[4] New cases have been described in more recent literature, including the first described case of Liddle syndrome due to two separate mutations, each with possible synergistic effects on the other.[5][6][7]

Researchers have not extensively studied the incidence of Liddle syndrome in the hypertensive population. However, Lin-Ping Wang et al and Liu et al have studied the prevalence of Liddle syndrome. They found that among younger Chinese individuals with unexplained resistant hypertension, the prevalence of Liddle syndrome was 1.52% and 1.72%, respectively.[1][8] In the first study by Lin-Ping Wang et al, only participants with hypokalemia underwent genetic testing. Notably, Liddle syndrome can also present in patients with potassium levels within the reference range. Therefore, if future studies were to evaluate the prevalence of Liddle syndrome in patients with normal serum potassium levels and resistant hypertension, the rate would likely be higher.[9] Furthermore, no predisposition based on race or sex has been identified. Researchers in one study of veterans in Northwest Louisiana, United States, concluded that approximately 6% had biochemical profiles consistent with Liddle syndrome, an unusually high prevalence for a hypertensive population.[10] Liddle syndrome may exhibit heterogeneous distribution because the gene encoding the α subunit is polymorphic.[11]

ENaCs are present in the distal colon, ducts of exocrine glands, lungs, placenta, dendritic cells, and the apical surface of the distal nephron epithelium (see Figure. Down-Regulation of Mutation in the Epithelial Sodium Channel (ENaC) Expression via Mineralocorticoid Receptors and Ubiquitylation).[3][12][13] Patients with Liddle syndrome have abnormal ENaC function in distal nephrons due to genetic mutations in 1 of the 3 subunits. In most of these mutations, the degradation of the sodium channels is impaired; therefore, the number of these channels on the apical surface of the distal nephron increases inappropriately.[14] However, a minority of cases are due to an increased open-state probability of ENaC.[15] Under normal conditions, the regulation of the ENaC is mediated through the binding of neural precursor cell expressed developmentally down-regulated 4-2 (Nedd4-2), a ubiquitin ligase, to the proline-rich PY motif of the ENaC subunit. This interaction ensures the subunit is tagged for degradation in a ubiquitination process. Aldosterone inhibits this process by inducing serum and glucocorticoid-regulated kinase 1 (SGK-1)–mediated phosphorylation of Nedd4-2, causing increased ENaC expression, leading to increased sodium reabsorption. In most cases of Liddle syndrome, the PY motif is truncated and cannot be tagged for degradation. Therefore, an increase in apical density of ENaC at the cell surface leads to increased sodium absorption, extracellular volume expansion, and hypertension. This process is similar to the effects of aldosterone, giving rise to the term pseudohyperaldosteronism.[16] The sodium feedback inhibition system is also impaired in patients with Liddle syndrome.[17] Typically, increased intracellular sodium in distal nephron cells inhibits apical epithelial sodium channels, but in Liddle syndrome, the channel becomes insensitive to sodium concentration. Increased numbers of sodium channels cause increased sodium reabsorption, which results in chronic volume retention, hypertension, and suppression of renin and aldosterone secretion.[18] Renal biopsies show atrophy of juxtaglomerular cells due to chronically suppressed renin and aldosterone levels, even after empirical treatment with triamterene.

The sodium feedback inhibition system is also impaired in patients with Liddle syndrome.[17] Typically, increased intracellular sodium in distal nephron cells inhibits apical epithelial sodium channels, but in Liddle syndrome, the channel becomes insensitive to sodium concentration. Increased numbers of sodium channels cause increased sodium reabsorption, which results in chronic volume retention, hypertension, and suppression of renin and aldosterone secretion.[18] Renal biopsies show atrophy of juxtaglomerular cells due to chronically suppressed renin and aldosterone levels, even after empirical treatment with triamterene. Additionally, the increased influx of sodium through ENaCs causes several different effects on other channels within the membrane. First, increased sodium-potassium adenosine triphosphatase (Na+/K+, ATPase pump) activity at the basolateral membrane increases potassium influx into the cell from the basolateral side. Second, the depolarization of the cell's apical membrane secondary to sodium entry causes potassium secretion through apical potassium channels. As a result, potassium is excreted in the urine, causing hypokalemia and metabolic alkalosis.[19]

Patients with Liddle syndrome can be symptomatic or asymptomatic. The syndrome usually presents with early-onset, resistant hypertension between ages 11 to 31 due to excess sodium reabsorption in the distal nephron; however, it may take years or decades for clinicians to establish the final diagnosis. Hypertension due to Liddle syndrome is responsive to a sodium-restricted diet and may present with headache, dizziness, retinopathy, chronic kidney disease, left ventricular hypertrophy, or sudden death.[9] Because patients have resistant hypertension, hypokalemia, and ventricular hypertrophy, they can develop cardiac arrhythmias, potentially leading to sudden death. Significant hypokalemia can cause muscle weakness, polyuria, and polydipsia. Hypokalemia and metabolic alkalosis occur due to excessive potassium loss in the urine secondary to sodium reabsorption.[20][21] The incidence of hypertension and hypokalemia in patients with Liddle syndrome is approximately 92.2% and 69.8%, respectively.[4] About 52.6% of patients with Liddle syndrome also present with hypoaldosteronism. Therefore, clinicians should also consider genetic testing for Liddle syndrome in patients who do not have the classic signs of hypertension or hypokalemia. The genetic testing is usually completed for these individuals due to a significant family history of the syndrome.

Patients with Liddle syndrome often present with secondary or resistant hypertension. Laboratory investigation may reveal hypokalemia and metabolic alkalosis.[22] Primary hyperaldosteronism can present with similar clinical features and biochemical abnormalities. Renin and aldosterone levels should be measured to differentiate between true hyperaldosteronism and pseudohyperaldosteronism. In patients with Liddle syndrome, renin and aldosterone levels are low or normal. Conversely, patients with hyperaldosteronism have elevated aldosterone levels. Spironolactone is ineffective for treating Liddle syndrome due to low or normal levels of aldosterone.[23] Ultimately, the diagnosis is confirmed by the identification of an abnormal gene regulating the ENaC. Clinicians should consider genetic testing in young patients with hyporeninemic hypertension to allow for timely diagnosis and mitigation of complications. Notably, whole-exome sequencing may be considered when multiple mutated genes are a consideration.[7]

Low levels of aldosterone render spironolactone ineffective in patients with Liddle syndrome. The treatment of choice is amiloride, which directly inhibits the ENaC. Amiloride is prescribed daily at doses ranging from 5 to 20 mg. Amiloride is considered safe to use in pregnancy, and doses may need to be adjusted up to a maximum of 30 mg.[24] Triamterene, another potassium-sparing diuretic with a similar mechanism of action to amiloride, can also treat Liddle syndrome. A sodium-restricted diet has a synergistic effect with these medications.[25] However, excessive sodium accumulation on the receptor makes it unavailable for elimination by the medication.[26] If renal function is normal, then hyperkalemia is very rare. Avoidance of excessive potassium in the diet is suggested, along with the use of potassium-sparing diuretics. If blood pressure is not controlled with potassium-sparing medications, other antihypertensive agents may be used to help achieve blood pressure targets and reduce cardiovascular risk. Caution is needed when using hydrochlorothiazide as a component of fixed-dose combination medications. Other classes of medications, such as β-blockers and vasodilators, could be very effective in controlling blood pressure.[26]

Low plasma renin levels with associated hypertension can be classified as follows: Low renin level with low aldosterone level Low renin level with aldosterone within the reference range Low renin level with elevated aldosterone level [27] Liddle syndrome is classified under low renin level with low aldosterone level. Other causes of hypertension that are classified under low renin level with low aldosterone level are as follows: Apparent mineralocorticoid excess 11β-hydroxyl deficiency 17α-hydroxyl deficiency Gordon syndrome Mineralocorticoid receptor-activating mutation Glucocorticoid resistance Ectopic adrenocorticotropic hormone production Excessive licorice use [28] Mineralocorticoid excess is an autosomal recessive syndrome due to 11β-hydroxysteroid dehydrogenase type 2 enzyme deficiency. This enzyme converts cortisol (active) into cortisone (inactive), which cannot bind to the mineralocorticoid receptor.[29] The chronic consumption of licorice, which contains glycyrrhizic acid, also inhibits this enzyme and presents with similar effects.[30] Gordon syndrome is an autosomal dominant condition caused by a mutation in a gene responsible for ion transport in the kidney, increasing sodium reabsorption and decreasing potassium excretion.[31]

Patients with Liddle syndrome typically respond well to medical therapy with potassium-sparing diuretics. However, results from current studies have not adequately evaluated the long-term mortality of Liddle syndrome. Clinicians often undertreat and misdiagnose this syndrome, and further studies are needed to better define the morbidity and mortality of secondary hypertension. Prognosis may also depend on healthcare access, as described in a reported case of a patient who lacked access to ENaC blockers and exhibited a limited therapeutic response to alternative therapies.[32]

Because of resistant hypertension, patients may develop end-organ damage, including myocardial infarction, transient ischemic attack or cerebrovascular accident, pulmonary edema, congestive heart failure, and left ventricular hypertrophy.[33] Earlier diagnosis and appropriate treatment can delay or prevent end-organ damage.

Patients should be counseled about the risks associated with resistant hypertension and educated about the importance of treatment adherence to minimize the risk of myocardial infarction and stroke. Therefore, they should be advised to maintain regular follow-up with their clinicians. Moreover, clinicians should emphasize the importance of a low-sodium and high-potassium diet, consistent medication use, and adequate blood pressure control.

Missed or delayed diagnosis of Liddle syndrome can lead to adverse clinical outcomes; therefore, early diagnosis is essential. Coordination between general pediatricians and pediatric nephrologists is necessary to ensure timely diagnosis and management. Genetic testing should be offered to family members of affected individuals. Genetic testing is available through the Genetic Testing Registry, and the geneticists can sequence exon 13 of the SCNN1B and SCNN1G genes to confirm the diagnosis.